alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Exhibit 12

                     GE GLOBAL INSURANCE HOLDING CORPORATION
                                AND SUBSIDIARIES

                Computation of Ratio of Earnings to Fixed Charges

<TABLE>
<CAPTION>
                                                        Year ended December 31,
                                             --------------------------------------------
 (In millions)                                 1996     1995     1994     1993     1992
                                             --------------------------------------------
 Earnings:
<S>                                            <C>       <C>      <C>       <C>      <C>
   Earnings before income taxes                $780     $561     $409     $395     $370
   Add:  Minority interest in net earnings
      of consolidated subsidiaries (1)           84       95       97       92       94
   Fixed charges                                 47       20        3        2        1
                                               ----     ----     ----     ----     ----
                                               $911     $676     $509     $489     $465
                                               ====     ====     ====     ====     ====
Fixed charges:
   Minority interest in net earnings of
      consolidated subsidiaries (2)            $110     $115     $108     $111     $113
   Interest expense                              47       20        3        2        1
                                               ----     ----     ----     ----     ----
                                               $157     $135     $111     $113     $114
                                               ====     ====     ====     ====     ====

Ratio of earnings to fixed charges             5.80     5.01     4.59     4.33     4.08
                                               ====     ====     ====     ====     ====


<FN>
(1)  Minority  interest in net earnings of  consolidated  subsidiaries  includes
     earnings from purchased affiliates and dividends on subsidiary's  preferred
     stock.

(2)  The  fixed  charges  amounts  for  minority  interest  in net  earnings  of
     consolidated subsidiaries represent the pretax earnings amounts which would
     be required to cover such fixed charges as calculated below:
</FN>
</TABLE>
                      Earnings From Purchased Affiliates or
                Subsidiary's Preferred Stock Dividend Requirement
               ---------------------------------------------------
                             100% - Income Tax Rate

     The  income  tax rate is based on the  relationship  of the  provision  for
     income tax  expense to  earnings  before  income  taxes for the  respective
     period.
# C_2015279EN.01006202.xml

| 24.8.2015 | EN | Official Journal of the European Union | C 279/62 |
| --- | --- | --- | --- |

24.8.2015

EN

Official Journal of the European Union

C 279/62

---

Order of the Civil Service Tribunal of 13 July 2015 — Carreira v ESMA

(Case F-69/14) (1)

(2015/C 279/81)

Language of the case: French

The President of the First Chamber has ordered that the case be removed from the register.

---

(1)  
  OJ C 380, 27/10/2014, p. 27.

---
Exhibit



EXHIBIT 10.11



Noble Corporation plc
Summary of Director Compensation


Annual Retainer. Noble Corporation plc, a company organized under the laws of England and Wales, (the “Company”) pays each of its non-employee directors an annual retainer of $50,000. Under the Noble Corporation plc 2017 Director Omnibus Plan (the “Director Plan”), non-employee directors may elect to receive up to all of the retainer in shares. The number of shares to be issued under the plan in any particular quarter is generally determined using the average of the reported high and low price of the shares on the NYSE on the date of the applicable quarterly Board meeting. 


Board Meeting Fees. In addition, the Company pays its non-employee directors a Board and committee meeting fee of $2,000.  The Company also reimburses directors for travel, lodging and related expenses they may incur in attending Board and committee meetings, and related activities in connection with the duties as director.


Committee Fees. The chair of the audit committee and the compensation committee receives an annual retainer of $20,000, and the chair of each other standing Board committee receives an annual retainer of $10,000. The lead director also receives an annual fee of $22,500.


Equity Compensation. Under the Director Plan, each annually-determined award of a variable number of shares is made on a date selected by the Board, or if no such date is selected by the Board, the date on which the Board action approving such award is taken. The compensation committee has adopted a policy that all awards made to directors under the Director Plan will include a one-year vesting period.  In addition, each award will be evidenced by a written agreement that includes such terms and conditions not inconsistent with the terms and conditions of the Director Plan as the Board considers appropriate in each case.
#### People of the State of Illinois, Plaintiff-Appellee, v. George William Smith, Jr., Defendant-Appellant.

Gen. No. 68-64. (Abstract of Decision.)

Second District.

April 10, 1969.

Joanne Sevcik Shea, of Riverside, for appellant; Bruno W. Stanczak, State’s Attorney of Lake County, of Waukegan, and John Hoogasian, Assistant State’s Attorney, for appellee.

Opinion by

JUSTICE ABRAHAMSON.

Not to be pubished in full.
Editorial Note on Part 868
Editorial Note: Nomenclature changes to part 868 appear at 73 FR 35341, June 23, 2008.

§ 868.2775 Electrical peripheral nerve stimulator. ( a ) *Identification.* An electrical peripheral nerve stimulator (neuromuscular blockade monitor) is a device used to apply an electrical current to a patient to test the level of pharmacological effect of anesthetic drugs and gases.
( b ) *Classification.* Class II (performance standards).
§ 520.2200 Sulfachlorpyridazine. ( a ) *Specifications.* ( 1 ) Sodium sulfachlorpyridazine powder.
( 2 ) Each milliliter (mL) of suspension contains 50 milligrams (mg) of sodium sulfachlorpyridazine.
( b ) *Sponsor.* See No. 016592 in § 510.600(c) of this chapter.
( c ) *Related tolerances.* See § 556.630 of this chapter.
( d ) *Conditions of use.* It is used as follows: ( 1 ) *Calves* — ( i ) *Amount.* Administer 30 to 45 mg sulfachlorpyridazine powder per pound (/lb) of body weight per day in milk or milk replacer in divided doses twice daily for 1 to 5 days.
( ii ) *Indications for use.* For the treatment of diarrhea caused or complicated by *Escherichia coli* (colibacillosis).
( iii ) *Limitations.* Treated ruminating calves must not be slaughtered for food during treatment or for 7 days after the last treatment. A withdrawal period has not been established for this product in preruminating calves. Do not use in calves to be processed for veal. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
( 2 ) *Swine* — ( i ) *Amount.* Administer 20 to 35 mg/lb body weight per day in divided doses twice daily for 1 to 5 days in drinking water or an oral suspension containing 50 mg per mL.
( ii ) *Indications for use.* For the treatment of diarrhea caused or complicated by *E. coli* (colibacillosis).
( iii ) *Limitations.* Treated swine must not be slaughtered for food during treatment or for 4 days after the last treatment. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[75 FR 10166, Mar. 5, 2010, as amended at 79 FR 28829, May 20, 2014; 81 FR 17607, Mar. 30, 2016; 81 FR 94990, Dec. 27, 2016; 88 FR 27699, May 3, 2023]
_____________

No. 95-2514WM

_____________

United States of America, *

*

Appellee, * Appeal from the United States

* District Court for the Western

v. * District of Missouri.

*

Deon Love, * [UNPUBLISHED]

*

Appellant. *

_____________

Submitted: December 7, 1995

 Filed: December 13, 1995

_____________

Before FAGG, LOKEN, and MORRIS SHEPPARD ARNOLD, Circuit Judges.

_____________

PER CURIAM.

Deon Love appeals the drug-related sentence imposed by the district

court under the sentencing guidelines. Love contends he was entitled to

a reduction to a sentencing range of 151-188 months because of Love's role

in the offense. We disagree.

At sentencing, the district court granted the government's motion for

a downward departure and sentenced Love to 84 months imprisonment and five

years supervised release. Because Love's 84-month sentence represents a

downward departure from the guideline range sought by Love, Love's sentence

is not reviewable. See United States v. Baker, 64 F.3d 439, 441 (8th Cir.

1995). 

We affirm Love's sentence.
-2-

A true copy.

Attest:

CLERK, U.S. COURT OF APPEALS, EIGHTH CIRCUIT.
#### § 720.6 Amendments to statement.

Changes in the information requested under §§ 720.4 (a)(3) and (a)(5) on the ingredients or brand name of a cosmetic product should be submitted by filing an amended Form FDA 2512 within 60 days after the product is entered into commercial distribution. Other changes do not justify immediate amendment, but should be shown by filing an amended Form FDA 2512 within a year after such changes. Notice of discontinuance of commercial distribution of a cosmetic product formulation should be submitted by Form FDA 2514 within 180 days after discontinuance of commercial distribution becomes known to the person filing.

[57 FR 3130, Jan. 28, 1992, as amended at 67 FR 9587, Mar. 4, 2002]
**Exhibit 32.2**

 

**CERTIFICATION PURSUANT TO**

 

**18 U.S.C. SECTION 1350,**

 

**AS ADOPTED PURSUANT TO**

 

**SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

 

Inconnection with the Quarterly Report of Ebix, Inc. (the “Company”) on Form10-Q for the quarterly period ended September 30, 2004, as amended byAmendment No. 1 thereto filed with the Securities and Exchange Commission onthe date hereof (as so amended the “Report”), I, Richard J. Baum, ChiefFinancial Officer of the Company, certify, pursuant to 18 U.S.C. 1350, as adoptedpursuant to 906 of the Sarbanes-Oxley Act of 2002, that:

 

1.The Report fully complies with the requirements of section 13(a) or15(d) of the Securities Exchange Act of 1934; and

 

2.The information contained in the Report fairly presents, in all materialrespects, the financial condition and results of operations of the Company.

 

 
| By:                      | /s/  Richard J. Baum |   |
|--------------------------|----------------------|--------|
|                     |
| Name:                    | Richard  J. Baum     |   |
|                     |
| Chief  Financial Officer |
|                     |
| May  20, 2005            |
|                          |                      |        |  |

 

1

----
§ 524.2101 Selenium disulfide suspension. ( a ) *Specifications.* The product contains 0.9-percent weight in weight (w/w) selenium disulfide (1-percent weight in volume (w/v)).
( b ) *Sponsors.* See Nos. 000061 and 017135 in § 510.600(c) of this chapter.
( c ) *Conditions of use on dogs* — ( 1 ) *Indications for use.* For use as a cleansing shampoo and as an agent for removing skin debris associated with dry eczema, seborrhea, and nonspecific dermatoses.
( 2 ) *Amount.* One to 2 ounces per application.
( 3 ) *Limitations.* Use carefully around scrotum and eyes, covering scrotum with petrolatum. Allow the shampoo to remain for 5 to 15 minutes before thorough rinsing. Repeat treatment once or twice a week. If conditions persist or if rash or irritation develops, discontinue use and consult a veterinarian.
[47 FR 53351, Nov. 26, 1982, as amended at 48 FR 32762, July 19, 1983; 54 FR 36962, Sept. 6, 1989; 56 FR 9623, Mar. 7, 1991; 58 FR 41025, Aug. 2, 1993; 63 FR 26981, May 15, 1998; 70 FR 50183, Aug. 26, 2005; 84 FR 39184, Aug. 9, 2019; 88 FR 27700, May 3, 2023]
EXHIBIT 15.1

May 17, 2000

BankFirst Corporation
625 Market Street
Knoxville, Tennessee  37902

We have reviewed,  in accordance  with standards  established by the AICPA,  the
unaudited interim financial  information of BankFirst  Corporation (the Company)
as of March 31, 2000 and for the  year-to-date  periods ended March 31, 2000 and
1999 as indicated in our report dated May 8, 2000. Because we did not perform an
audit, we expressed no opinion on that information.

We are aware that our  report  referred  to above,  which was  included  in your
quarterly  report on Form 10-Q, is being  incorporated  by reference in the Form
S-8 Registration Statement.

We also are aware that our report referred to above, under Rule 436(c) under the
Securities Act of 1933, is not considered a part of the  registration  statement
prepared or certified by an accountant  or a report  prepared or certified by an
accountant within the meaning of Sections 7 and 11 of the Act.


                                      Crowe, Chizek and Company LLP
EXHIBIT 99.2
                                                                    ------------

PRESS RELEASE DATED MAY 15, 2003

Lifeway Foods, Inc.
For Immediate Release

Lifeway Foods, Inc. Reports Record First Quarter Results: Net Income Up 122%
----------------------------------------------------------------------------

Morton Grove, IL, May 15, 2003 - Lifeway Foods, Inc. (Nasdaq: LWAY) today
reported financial results for the first quarter ended March 31, 2003. Lifeway
reported record revenues of $3.30 million, up 15 percent from last year's first
quarter revenues of $2.89 million. Net income rose 122% to $993,273 or $.24 per
share versus a net income of $447,558 or $.10 in 2002. Contributing to the
change in net income and earnings per share was a non-recurring gain of about
$1,246,287 from the disposition of real property and a change in the loss from
the sales of marketable securities approximately equal to $382,576.

Julie Smolyansky, President and CEO, commented, "We are extremely pleased with
our first quarter results. Our sales continue to be strong and we continue to
surpass our growth targets. In addition, we continue to penetrate the mainstream
market with our staple products, and have seen much improved growth of our newer
products such as SoyTreat(R), Organic Kefir, and especially, La Fruta.

Smolyansky added, "With the addition of the new and improved packaging for our
beverages coming in the later months, we feel even more confident that we can
surpass our goals and achieve record revenues and profits for the current 2003
year."

Lifeway is a manufacturer of cultured, probiotic and functional food products in
the health food industry, and is America's leading supplier of the cultured
dairy product known as kefir. The Company markets 12 flavors of kefir and does a
successful business exporting its products to Canada. The Company also
participates in the organic and soy markets with Lifeway OrganicTM, Organic
Kefir and Kefir Cheese, and America's first soy kefir, called SoyTreat(R).

For more information, contact Julie Smolyansky, President, Lifeway Foods, Inc.
at (847) 967-1010 or e-mail at info@lifeway.net or visit www.lifeway.net.

This news release contains forward-looking statements. Investors are cautioned
that actual results may differ materially from such forward-looking statements.
Forward-looking statements involve risks and uncertainties including, but not
limited to, competitive pressures and other important factors detailed in the
Company's reports filed with the Securities and Exchange Commission.
Editorial Note on Part 868
Editorial Note: Nomenclature changes to part 868 appear at 73 FR 35341, June 23, 2008.

§ 868.2300 Bourdon gauge flowmeter. ( a ) *Identification.* A bourdon gauge flowmeter is a device intended for medical purposes that is used in conjunction with respiratory equipment to sense gas pressure. The device is calibrated to indicate gas flow rate when the outflow is open to the atmosphere.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 868.9.
[47 FR 31142, July 16, 1982, as amended at 61 FR 1119, Jan. 16, 1996; 66 FR 38794, July 25, 2001]
#### § 584.200 Ethyl alcohol containing ethyl acetate.

The feed additive ethyl alcohol containing ethyl acetate meets the requirement of 27 CFR 21.62, being not less than 92.5 percent ethyl alcohol, each 100 gallons having had added the equivalent of 4.25 gallons of 100 percent ethyl acetate. It is used in accordance with good feeding practices in ruminant feed supplements as a source of added energy.

[46 FR 52333, Oct. 27, 1981, as amended at 72 FR 41620, July 31, 2007]
<Page>

                                                                   EXHIBIT 10.14

                                 SIXTH AMENDMENT
                                     TO THE
                            ALLEGIANCE TELECOM, INC.
                            1998 STOCK INCENTIVE PLAN
            (APPROVED BY THE BOARD OF DIRECTORS ON JANUARY 14, 2003)

WHEREAS, the Allegiance Telecom, Inc. 1998 Stock Incentive Plan (the "Plan") was
adopted by the Corporation's Board of Directors.

WHEREAS, the Corporation's Board of Directors is amending the Allegiance
Telecom, Inc. 1998 Stock Incentive Plan in accordance with Section 16 of such
Plan.

RESOLVED, that Section 17 of the Plan be amended and restated in its entirety as
follows:

          "1. AMENDMENT (INCLUDING REPRICING) AND SUBSTITUTION OF AWARDS UNDER
     THE PLAN.

     The terms of any outstanding award under the Plan may be amended from time
     to time by the Committee in its discretion in any manner that it deems
     appropriate (including, but not limited to, repricing of the award,
     extending the exercise period of the award, accelerating the vesting date
     of any award and/or payments thereunder and/or accelerating the date of
     lapse of restrictions on Shares); provided that, except as otherwise
     provided in Section 15, no such amendment shall adversely affect in a
     material manner any right of a participant under the award without his or
     her written consent. The Committee may, in its discretion, permit holders
     of awards under the Plan to surrender outstanding awards in order to
     exercise or realize rights under other awards, or in exchange for the grant
     of new awards, or require holders of awards to surrender outstanding awards
     as a condition precedent to the grant of new awards under the Plan.

     The term "repricing" means any of the following (or any other action that
     has the same effect as any of the following): (1) amending the terms of a
     stock option after it is granted to lower its exercise price; (2) any other
     action that is treated as a repricing under generally accepted accounting
     principles; and (3) canceling an option at a time when its exercise price
     is equal to or greater than the fair market value of the underlying stock,
     in exchange for another option, restricted stock, or other equity. A
     cancellation and exchange described in clause (3) of the preceding sentence
     will be considered a repricing regardless of whether the option, restricted
     stock or other equity is delivered simultaneously with the cancellation,
     regardless of whether it is treated as a repricing under generally accepted
     accounting principles, and regardless of whether it is voluntary on the
     part of the option holder. "
Exhibit 99.1
                                                                    ------------


                            CERTIFICATION PURSUANT TO
                             18 U.S.C. SECTION 1350
                               ADOPTED PURSUANT TO
                 SECTION 906 OF THE SARBANES--OXLEY ACT OF 2002

      In connection with the Quarterly Report of GVC Venture Corp. (the
"Company") on Form 10-QSB for the period ended December 31, 2002 as filed with
the Securities and Exchange Commission on the date hereof (the "Report"), I,
Marc Hanover, Vice President Finance and Treasurer, certify, pursuant to 18
U.S.C. ss. 1350, adopted pursuant to Section 906 of the Sarbanes--Oxley Act of
2002 that to my knowledge:

      (1)   The Report fully complies with the requirements of Section 13(a) of
            the Securities Exchange Act of 1934; and
      (2)   The information contained in the Report fairly presents, in all
            material respects, the financial condition and results of operations
            of the Company.


                                           /s/ Marc Hanover
                                           -------------------------------------
                                           Marc Hanover
                                           Vice-President, Finance and Treasurer
                                           (Principal Financial Officer and
                                           Principal Accounting Officer)



Date: February 4, 2003
Exhibit 16

                              [Letterhead of KPMG]

July 2, 2001

Securities and Exchange Commission
Washington, D.C. 20549

Ladies and Gentlemen:

      We were previously principal accountants for The CIT Group, Inc. ("CIT")
and, under the date of January 25, 2001, except for Note 25 regarding the
acquisition of CIT by Tyco International Ltd., which is as of March 13, 2001, we
reported on the consolidated financial statements of The CIT Group, Inc. and
subsidiaries for the years ended December 31, 2000 and 1999. On June 1, 2001 our
appointment as principal accountants was terminated. We have read CIT's
statements included under Item 4 of its Amendment No. 1 on Form 8-K/A dated July
2, 2001 and we agree with such statements.

Very truly yours,

/s/ KPMG LLP


                                      -1-